Dianthus Therapeutics
DNTH
74 hedge funds and large institutions have $769M invested in Dianthus Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 30 closing their positions.
136% more capital inflows, than outflows
Capital inflows: $136M | Capital outflows: $57.8M
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12.35% more ownership
Funds ownership: 88.85% → 101.2% (+12%)
7% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 30
3% less funds holding
Funds holding: 76 → 74 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$37.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.31M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.32M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$6.51M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.16M |
| 4 |
Walleye Capital
New York
|
-$5.71M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.28M |
DNTH Hedge Fund Activity: Q2 2024 in Review
74 of the 6,940 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2024, worth a combined $769M — down 1.7% from $782M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of DNTH and 28 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 19 added.
The largest buyer was BlackRock, adding an estimated $37.4M. The largest seller was Millennium Management, exiting entirely with an estimated $8.32M sold.
- 74 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2024, down from 76 in Q1 2024.
- Funds reported $769M of Dianthus Therapeutics stock for Q2 2024, down 1.7% quarter-over-quarter.
- 28 funds opened new Dianthus Therapeutics positions in Q2 2024 and 30 closed out, a net change of -2 holders.
- The largest Dianthus Therapeutics buyer in Q2 2024 was BlackRock, an estimated $37.4M added.
- The largest Dianthus Therapeutics seller in Q2 2024 was Millennium Management, an estimated $8.32M sold.
Based on aggregated 13F filings for Q2 2024.